ATOMOXETINE
Clinical Indication
Attention deficit hyperactivity disorder (ADHD)
Date of classification
January 2009
Orange
Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.